La Jolla Pharm

LJPC NASDAQ
5.84
-0.29
-4.73%
Opening 11:03 05/20 EDT
Open
6.05
Prev Close
6.13
High
6.10
Low
5.81
Volume
199.78K
Avg Vol (3M)
592.09K
52 Week High
38.39
52 Week Low
5.01
% Turnover
0.74%
Market Cap
158.26M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers La Jolla Pharm LJPC stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
MORE >

Recently

Name
Price
%Change